Viracta Therapeutics, Inc.

VIRX

US92765F1084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-20 pm EDT			5-day change	1st Jan Change
0.807 ^USD	0.00%		+4.67%	+41.58%

May. 14	Viracta Therapeutics Appoints Michael Faerm CFO	MT
May. 14	Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer	CI

Viracta Therapeutics, Inc. Announces That Gur Roshwalb Will Not Stand for Re-Election At the Company’s 2022 Annual Meeting of Stockholders

April 15, 2022 at 03:01 pm EDT

Viracta Therapeutics, Inc. announced that Gur Roshwalb will not stand for re-election at the Company's 2022 annual meeting of stockholders.

Latest news about Viracta Therapeutics, Inc.

Viracta Therapeutics Appoints Michael Faerm CFO	May. 14	MT
Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer	May. 14	CI
Viracta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial	Apr. 15	CI
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	Apr. 01	CI
Lenz Therapeutics, Graphite Bio Complete Merger; Combined Company Names New CFO	Mar. 21	MT
Viracta Therapeutics, Inc. Announces Executive Changes	Mar. 20	CI
Viracta Therapeutics, Inc. Announces Chief Financial Officer Changes	Mar. 20	CI
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Viracta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Viracta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Viracta Therapeutics, Inc. Provides Clinical Update	Jan. 04	CI
Viracta Therapeutics Announces Interim Data from Phase 1B/2 Clinical Trial of Nana-Val in Patients with Epstein-Barr Virus-Positive Solid Tumors That Show Confirms Tumor Responses At Higher Dose Levels	Dec. 04	CI
RBC Cuts Price Target on Viracta Therapeutics to $6 From $7, Keeps Outperform, Speculative Risk	Nov. 10	MT
Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
XOMA Earns $5 Million Milestone Upon US FDA Acceptance of Day One Biopharmaceuticals' NDA for Glioma Therapy	23-10-31	MT
Transcript : Viracta Therapeutics, Inc. - Special Call	23-10-04
Viracta Therapeutics, Inc.(NasdaqGS:VIRX) dropped from S&P Global BMI Index	23-09-18	CI
North American Morning Briefing : China Angst -2-	23-08-15	DJ
Viracta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Viracta Therapeutics, Inc. Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer	23-08-08	CI
HC Wainwright Lowers Price Target on Viracta Therapeutics to $10 From $33, Maintains Buy Rating	23-07-05	MT
Viracta Therapeutics to Expand Cohort of Patients in Virus-Associated Cancers Clinical Trial	23-06-28	MT
Viracta Therapeuticsâ€™ Pivotal Naval-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma	23-06-28	CI
RBC Cuts Price Target on Viracta Therapeutics to $7 From $8, Maintains Outperform, Speculative Risk Rating	23-05-09	MT

Chart Viracta Therapeutics, Inc.

Duration

Period

More charts

Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Companyâs lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-06-18 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.807 USD

Average target price

7 USD

Spread / Average Target

+767.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIRACTA THERAPEUTICS, INC.	+41.58%	31.69M
MODERNA, INC.	+41.79%	54.04B
IQVIA HOLDINGS INC.	-0.56%	41.92B
LONZA GROUP AG	+47.53%	41.96B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B

Other Biotechnology & Medical Research